Alexza Pharmaceuticals (ALXA) says it's submitted its responses to the European Medicines Agency regarding a list of questions posed to it in March 2012 about its Adasuve Marketing Authorization Application. The submitted responses address questions of deficiencies laid out in the EMA's Day 120 List of Questions. The firm expects to receive a follow up response regarding the submission in late September.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs